<DOC>
	<DOCNO>NCT02570789</DOCNO>
	<brief_summary>The purpose study ass whether certain metabonomics and/or lipidomics feature correlation pharmacokinetics , treatment sunitinib pazopanib first line predict toxicity efficacy sunitinib pazopanib metastatic clear cell renal cell carcinoma patient .</brief_summary>
	<brief_title>Evaluation Predictive Markers Toxicity Efficacy Patients With mccRCC Treated Anti-VEGF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Woman man ≥ 18 Years old , histologically proven metastatic clear cell ( al least clear cell predominant ) RCC , Good intermediate risk accord MSKCCcriteria , Subjects fall condition reimbursement sunitinib pazopanib context mRCC , Measurable disease base RECIST criterion ( version 1.1 ) , Subject give voluntary write informed consent , Subject investigator 's opinion , willing able comply protocol requirement , Subject ECOG ≤ 2 , Subject life expectancy ≥ 3 month , Concurrent treatment bisphosphonates denosumab allow however start screen study . If possible start new medication baseline metabolo lipidomotype first metabolo lipidomotypeanalysis avoid , Subjects recover side effect previous therapy grade 1 CTC v 4.0 criterion Patients nonclear cell RCC and/or sarcomatoid differentiation , Patients present type cancer disease within 5 year inclusion study ; absence cervical cancer basocellular carcinoma , Patients uncontrolled arterial hypertension , Patients uncontrolled hypo hyperthyroidism , Patient major surgery within 4 week enrolment , Patient myocardial infarction within 6 month prior enrolment NHYA class III otr IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia electrocardiographic evidence acute ischemia active conduction system abnormality , Patient another serious medical condition could potentially interfere completion study , Seropositive HIV , Subject know hepatitis B surface antigen positive active hepatitis C infection , Subject active systemic infection require treatment , Female subject pregnant breast feeding , Subject enrol another clinical trial and/or receive investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>